ArticleGland surgery2026
Minimally invasive video-assisted thyroidectomy (MIVAT) and thyroid cancer: a single centre 10-year follow-up.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer is the most frequent endocrine malignancy, has low recurrence rates and it is particularly common among young women. Minimally invasive video-assisted thyroidectomy (MIVAT), introduced about 25 years ago, is still the most widespread minimally endoscopic procedure. The aim of the study was to obtain long-term follow-up of oncological outcomes and postoperative complications after MIVAT, performed for differentiated thyroid carcinoma. Methods: In our retrospective observational study, we included 81 patients undergone to for differentiated thyroid carcinoma from January 2006 to December 2013 at the General Surgery Clinic of the University Hospital of Parma, Italy. We evaluated anamnesis, preoperative data, type of intervention and eventual conversion to traditional surgery, histological examination, postoperative complications, postoperative radio iodine therapy (RAI), keloid and hypertrophic scar, recurrence and re-intervention. Results: All patients underwent total thyroidectomy. In one case, a video-assisted central lymphoadenectomy was performed. A 2.8% conversion rate was found, and these four patients were excluded from the analysis. Postoperative adverse events reported were hemorrhage (1.23%), transient hypocalcemia (7.4%), permanent hypocalcemia (1.23%), permanent recurrent laryngeal nerve (RLN) palsy (1.23%), keloid scar (2.46%). Postoperative RAI was executed in 48 cases (59.2%). With a median follow-up of 14.86 years, only one patient presented a lateral cervical lymph node recurrence and required a lateral cervical lymphadenectomy. No cases of local relapses were reported and no patient died for causes correlated with thyroid carcinoma. Conclusions: Monitoring the results of our MIVAT procedures series with at least 10-year follow-up, we have found it safe concerning both postoperative complications and oncological outcomes, comparably with other minimally invasive thyroidectomies series and with conventional thyroidectomy. Particularly, among minimally invasive endoscopic techniques, MIVAT offers the best compromise between postoperative complications, costs, execution time and cosmetic results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.